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Abstract
Infection of macaques with the avirulent molecular clone SIVmac1A11 results in transient low
viremia and no disease. To investigate if this low viremia is solely due to intrinsic poor replication
fitness or is mediated by efficient immune-mediated control, 5 macaques were inoculated
intravenously with SIVmac1A11. Three animals that were depleted of CD8+ cells at the start of
infection had more prolonged viremia with peak virus levels 1 to 2 logs higher than those of 2
animals that received a non-depleting control antibody. Thus, CD8+ cell-mediated immune
responses play an important role in controlling SIVmac1A11 replication during acute viremia.
Simian immunodeficiency virus (SIV) infection of
macaques has proven useful for modeling HIV disease
pathogenesis and intervention strategies [1-3]. While
infection of macaques with most SIV isolates results even-
tually in an AIDS-like disease, there are also attenuated
isolates and clones. SIVmac1A11 is a molecular clone
originally derived from a virus isolate from an SIV-
infected macaque that was also the source of virulent
uncloned SIVmac251 isolates [4,5]. Although the kinetics
are slower than for other isolates, SIVmac1A11 replicates
well in vitro and is highly cytopathogenic (with induction
of syncytia) in T-cell lines and rhesus macaque peripheral
blood mononuclear cells (PBMC); SIVmac1A11 replicates
well in macrophage cultures [6]. In early studies, it was
observed that SIVmac1A11 inoculation of juvenile
macaques resulted in transient viremia and no disease,
even after prolonged follow-up for more than 12 years
([4]; unpublished observations). Subsequent studies doc-
umented that SIVmac1A11 inoculation of fetal and new-
born macaques also resulted in transient viremia and no
disease [7,8]. SIVmac1A11 has a tissue distribution dis-
tinct from that of virulent isolates [9].
Because of these unique properties, SIVmac1A11 has
proven useful to study determinants of viral virulence. The
genome of SIVmac1A11 has been sequenced, and recom-
bination experiments revealed that differences in more
than one region of the viral genome were responsible for
the lack of virulence [5,10]. SIVmac1A11 has also shown
promise as a live-attenuated vaccine in both infant and
juvenile/adult macaques [10-13].
The transient low-level viremia (peak levels ≤ 4 to 5 log
RNA copies per ml plasma) that results from SIVmac1A11
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infection suggests either poor intrinsic replication fitness
in vivo and/or relatively effective immune control. CD8+
cell depletion experiments (via administration of mono-
clonal antibody) have demonstrated the important role of
CD8+ cell-mediated immune responses in controlling
acute and chronic viremia with virulent SIV isolates (such
as SIVmac251; [14]) and chronic viremia with the attenu-
ated clone SIVmac239∆nef [15]; however, CD8+ cell
depletion had no detectable effect on viremia in animals
chronically infected with the more attenuated clone
SIVmac239∆3 [16] or with SIVmac1A11 (unpublished
data). To our knowledge, no CD8+ cell depletion experi-
ments have been performed during acute infection with
nonpathogenic SIV isolates.
Accordingly, we sought to determine the role of CD8+
cell-mediated immune responses on acute SIVmac1A11
viremia. Animals in this study were juvenile rhesus
macaques (Macaca mulatta; ~1 year of age), housed in
accordance with American Association for Accreditation
of Laboratory Animal Care Standards with strict adher-
ence to the "Guide for the Care and Use of Laboratory Ani-
mals" [17]. When necessary, the animals were
immobilized with ketamine HCL (Parke-Davis, Morris
Plains, New Jersey) 10 mg/kg injected intramuscularly.
All 5 macaques were inoculated intravenously with a high
dose of SIVmac1A11 (5 × 105 50% tissue culture infec-
tious doses, grown in CEMx174 cells). Immediately
before virus inoculation, 3 animals were depleted of
CD8+ cells via administration of the anti-CD8 antibody
cM-T807 at a dose of 50 mg/kg body weight (adminis-
tered slowly intravenously); the same dose was repeated 3
weeks later. This dosage regimen, which is higher than the
regimen used in previous CD8+ cell depletion studies
[14,18], was selected because it gives more prolonged
depletion of CD8+ cells (K. Reimann, personal communi-
cation). In the current study, CD8+ cells (both
CD8+CD3+ T lymphocytes and CD8+CD3- NK cells) in
peripheral blood were undetectable or low (< 1% of lym-
phocytes; ≤ 40 cells per µl blood) for 21 to 35 days after
treatment (Fig. 1B,C). The remaining 2 animals received a
control (i.e., non-depleting) human immunoglobulin
preparation (Aventis Gammar-P I.V.) at the same dosage
regimen (50 mg/kg at 0 and 3 weeks).
The 2 control-antibody treated animals had peak plasma
viral RNA levels of 4 to 7 × 103 copies/ml at 3 days after
virus inoculation (Fig. 1A). For one animal (number
35391), a second smaller peak of viremia was observed on
day 17. The levels of viremia in these 2 control animals are
thus similar to those described previously for
SIVmac1A11-infected juvenile macaques [19]. The 3
CD8+ cell-depleted animals had viral RNA levels during
the first 7 days that were indistinguishable from those of
the control animals, suggesting that during these early
stages, CD8+ cells had no detectable role in controlling
SIVmac1A11 replication. However, after an initial decline,
viral RNA levels in the CD8+ cell-depleted animals
increased from day 10 onwards and reached peak levels of
45,000 to 790,000 on day 17; these values were 1–2 log
higher than those of the control animals (p = 0.015, two-
tailed t-test comparing day 17 values, and area-under-the
curve values for day 0 to 35) and only ~1–2 log lower than
peak viremia levels observed with the pathogenic molecu-
lar clone SIVmac239 [20-22]. Despite this higher viremia
in the CD8+ cell-depleted animals, there were no signifi-
cant changes in CD4+CD3+ T lymphocyte counts in
peripheral blood (Fig. 1D); this study was not designed to
monitor CD4+CD3+ T lymphocyte levels in gut-associ-
ated lymphoid tissue. Plasma viral RNA levels declined
upon the return of CD8+ cells and became undetectable
from 28 to 35 days of infection onwards throughout the
rest of the observation period (> 6 months). These results
indicate that CD8+ cells play a major role in controlling
SIVmac1A11 replication because in their absence, peak
viremia was higher and the acute viremia phase was signif-
icantly prolonged.
Because the cM-T807 antibody depletes both CD8+ T lym-
phocytes as well as NK cells, the relative contribution of
each cell type could not be determined. CD8+ T cells and
NK cells inhibit virus replication in vitro through a variety
of mechanisms, including cytolytic and non-cytolytic
pathways [23-25]. Most NK cells also have the low-affinity
Fc-gamma III receptor (CD16), which triggers antibody-
dependent cellular cytotoxicity (ADCC) and antibody-
dependent cell-mediated virus inhibition (ADCVI).
ADCVI is similar to ADCC but is a measure of virus inhi-
bition, rather than target cell cytotoxicity. ADCVI has been
observed ex vivo with serum and effector cells from HIV-
infected humans and SIV-infected macaques [26](Forthal
et al, manuscript submitted). Forthal et al. have also dem-
onstrated that ADCVI-mediating antibodies can be found
early during HIV-1 infection and reduce HIV-1 yield both
by lysis of infected target cells and by the release of beta-
chemokines from NK effector cells [27,28]. In the current
study, the SIVmac1A11-infected animals had detectable
antiviral IgG antibodies (as measured by whole SIV ELISA
techniques; [29]) at ~2 weeks of infection, and the CD8+
cell-depleted animals had a more rapid increase in anti-
body titers, possibly due to more antigenic stimulation
(Fig. 1E). Early plasma samples were also tested for
ADCVI activity; pronounced inhibition (> 70%) was
observed in plasma collected at 17 days of infection at a
1:100 dilution in all animals (Fig. 1F). Thus, some of the
loss of viremia control following CD8+ cell depletion
could be due to the loss of CD8+ NK cells that would
likely serve as ADCVI effector cells.Virology Journal 2006, 3:22 http://www.virologyj.com/content/3/1/22
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Effect of CD8+ cell depletion on SIVmac1A11 infection: viral and immunologic parameters Figure 1
Effect of CD8+ cell depletion on SIVmac1A11 infection: viral and immunologic parameters. Five animals were 
inoculated with SIVmac1A11 at time zero. Three animals were CD8+ cell depleted via administration of cM-T807 while the 
other 2 animals received control antibody. (A) Viral RNA levels in plasma (measured by bDNA assay, with a limit of detection 
of 125 copies/ml; [18]). Results from virus isolation from 1 million PBMC, using CEMx174 cells and p27 measurement [34] are 
given as positive (+) or negative (-). The absolute counts of CD8+CD3+ T lymphocytes, CD8+CD3- NK cells and CD4+CD3+ 
T lymphocytes were measured according to flow cytometry techniques described previously [18], and are presented in graphs 
B through D, respectively. (E) SIV-specific IgG titers measured by a whole SIV ELISA [29]; although the CD8+ cell depleted ani-
mals made a faster response than the undepleted animals, from week 6 onwards, both animal groups had similar antiviral IgG 
titers (1: 6,400 to 1: 25,600). (F) Antiviral activity of plasma collected at 17 days after SIVmac1A11 inoculation as measured in a 
ADCVI assay, described in detail elsewhere (Forthal et al., submitted for publication). Briefly, CEMx174 cells were infected with 
SIVmac1A11 at a MOI of 0.01; 48 hours later, cells were plated in 96-well plates at 50,000 cells per well. Plasma samples 
(including negative and positive control samples) were added at a 1:100 dilution and human PBMC effector cells were added to 
obtain an effector:target cell ratio of 10:1. Five days later, SIV p27 was measured in supernatant fluid using a commercially avail-
able ELISA (Zeptometrix Corporation, Buffalo, NY). Percent inhibition by the plasma samples collected on day 17 was calcu-
lated relative to the level of virus replication in the presence of plasma collected on day zero (before SIVmac1A11 inoculation); 
the presented values represent mean +/- SEM of 4 separate assays (with effector PBMC of 4 different donors). In the absence 
of effector cells, no significant inhibition (≤ 11%) was observed (data not shown).Virology Journal 2006, 3:22 http://www.virologyj.com/content/3/1/22
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Levels of interleukin-12 and interferon-α were measured
in plasma using commercial ELISA-kits (monkey IL-12
ELISA, U-CyTech, Utrecht, the Netherlands; human inter-
feron-α ELISA kit, PBL Biomedical Laboratories, Piscata-
way, NJ). Although variable levels were detected for both
cytokines, there was no correlation with virus levels (data
not shown).
In conclusion, this experiment demonstrated that the
acute low-level viremia of SIVmac1A11 which is observed
following inoculation of untreated animals cannot be
explained solely by poor intrinsic replication fitness of the
virus; instead, immune responses that are dependent on
CD8+ cells limit the magnitude and duration of acute
viremia. Viremia of SIVmac1A11 has always been
observed to be transient (~2–6 weeks), even following
inoculation of fetal and newborn macaques [7,8]. This
indicates that these antiviral immune responses are not
abrogated or prevented from emerging during acute
SIVmac1A11 viremia and suggests that there is relatively
little or no virus-induced immunosuppression. Rather,
the anti-SIVmac1A11 immune responses appear able to
induce a long-term asymptomatic infection [10]. This is in
contrast to infection with virulent SIV isolates, for which
irreversible damage to the immune system appears to
occur early during the course of infection [9,30-32].
Accordingly, further experiments that combine avirulent
strains such as SIVmac1A11 infection with selective deple-
tions of immune cell populations may prove to be a useful
and sensitive model to further unravel precisely the
immune responses that are important to control viremia,
but that may be difficult to detect during infection with
virulent isolates. Attempts to boost or preserve such
immune responses may lead to immunotherapeutic strat-
egies that are more effective in achieving long-term con-
trol on viremia of virulent virus isolates, including HIV-1.
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